Boehringer Ingelheim advances cancer antibody-drug conjugate portfolio with asset from AimedBio

CAR-T Digest - August 2020

15 October 2025: Boehringer Ingelheim advances cancer antibody-drug conjugate portfolio with asset from AimedBio

Boehringer Ingelheim and AimedBio have entered a global collaboration and licensing agreement to co-develop a novel antibody-drug conjugate (ADC) designed to treat a broad range of cancers with high unmet medical needs
Under the agreement terms, AimedBio will receive up to $991 million, including upfront, development, regulatory, and commercial milestone payments, along with tiered royalties on future global sales, reflecting Boehringer’s strong commitment to advancing next-generation oncology therapies
The ADC targets a tumor-selective surface protein that is highly expressed in multiple cancer types but minimally present in normal tissues, enabling precise tumor targeting and reduced off-target toxicity
Developed using AimedBio’s proprietary ADC platform, the therapy couples a monoclonal antibody with an exatecan-derived cytotoxic payload, aiming to deliver potent, targeted cell killing and overcome treatment resistance
The program is expected to enter first-in-human clinical trials in 2026, further strengthening Boehringer’s expanding ADC portfolio, led by its subsidiary NBE Therapeutics, as part of its broader strategy to transform cancer treatment